Merieux Equity Partners
Mérieux Equity Partners is a leading European healthcare-specialized investment firm founded in 2009, managing over €1.6 billion in assets through two dedicated platforms: Innovation (venture capital) and Buyout (growth and buyout). The firm supports companies ranging from start-ups to established leaders across Europe and North America.
Key facts
Recent exits
Coverage notes
7 funds tracked, 56 portfolio companies (34 active · 22 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
56 companiesFunds & portfolio
Every fund Merieux Equity Partners has raised, with its portfolio companies. Hand-checked from public filings.
Mérieux Participations 5Buyoutinvesting2026 · 0yr€335M0 active
No portfolio companies tracked yet.
Mérieux Innovation 2VCinvesting2024 · 2yr€380M5 active
Unrealized
5 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Healthcare |  France | 2024 | |
| Healthcare |  Germany | 2025 | |
| HealthTech |  Spain | 2026 | |
| Biotech | Spain | 2026 | |
| MedTech |  UK | 2024 |
France· Entry 2024Germany· Entry 2025Spain· Entry 2026Spain· Entry 2026UK· Entry 2024Mérieux Participations 4Buyoutinvesting2023 · 3yr€500M3 active
Unrealized
3 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Healthcare |  Belgium | 2022 | |
| Pharma | France | 2025 | |
| Healthcare | France | 2023 |
Belgium· Entry 2022France· Entry 2025France· Entry 2023Mérieux Participations 3Buyoutharvesting2019 · 7yr€350M7 active · 4 realized
Unrealized
7 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Healthcare | France | – | |
| HealthTech | France | 2021 | |
| Healthcare | France | 2021 | |
| Healthcare | France | 2021 | |
| Healthcare | France | 2020 | |
| Healthcare | France | 2022 | |
| Healthcare | Belgium | 2021 |
FranceFrance· Entry 2021France· Entry 2021France· Entry 2021France· Entry 2020France· Entry 2022Belgium· Entry 2021Realized
4 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Healthcare | France | 2019 | 2022 | Trade Sale | – | ||
| Healthcare | France | 2019 | 2024 | Trade Sale | – | ||
| Healthcare | France | 2020 | 2025 | Trade Sale | – | ||
| Healthcare |  Switzerland | 2021 | 2026 | Secondary | – |
Mérieux Participations 2Buyoutdivesting2014 · 12yr€200M4 active · 3 realized
Unrealized
4 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Healthcare | France | 2018 | |
| Pharma | France | 2016 | |
| Healthcare | Belgium | 2018 | |
| Healthcare | France | 2018 |
France· Entry 2018France· Entry 2016Belgium· Entry 2018France· Entry 2018Realized
3 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Healthcare | Israel | 2015 | – | – | – | – | |
| Healthcare | France | 2017 | 2021 | Trade Sale | – | ||
| Healthcare | France | 2016 | 2022 | Secondary | – |
Mérieux Innovation 1VCdivesting2014 · 12yr€120M15 active · 14 realized
Unrealized
15 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| MedTech | France | 2021 | |
| Healthcare | Belgium | 2021 | |
| Healthcare | UK | 2023 | |
| MedTech | France | 2022 | |
| Healthcare | France | 2020 | |
| Healthcare | France | 2020 | |
| Healthcare |  Netherlands | 2023 | |
| Healthcare |  US | 2018 | |
| MedTech | France | 2016 | |
| Healthcare | Netherlands | 2020 | |
| Healthcare | Belgium | 2020 | |
| MedTech | France | 2021 | |
| Healthcare | Belgium | 2020 | |
| Biotech | France | 2022 | |
| Healthcare | US | 2020 |
France· Entry 2021Belgium· Entry 2021UK· Entry 2023France· Entry 2022France· Entry 2020France· Entry 2020Netherlands· Entry 2023US· Entry 2018France· Entry 2016Netherlands· Entry 2020Belgium· Entry 2020France· Entry 2021Belgium· Entry 2020France· Entry 2022US· Entry 2020Realized
14 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Healthcare | France | 2012 | 2014 | Trade Sale | – | ||
| Healthcare | France | 2012 | 2019 | Trade Sale | – | ||
| Healthcare | US | 2017 | 2022 | Trade Sale | – | ||
| Healthcare | US | 2014 | 2016 | Trade Sale | – | ||
| Healthcare | France | 2023 | 2025 | Trade Sale | – | ||
| Biotech | France | 2022 | 2023 | Trade Sale | – | ||
| Healthcare | France | 2019 | 2024 | Trade Sale | – | ||
| Healthcare | US | 2015 | 2016 | Trade Sale | – | ||
| Healthcare | France | 2017 | 2023 | Trade Sale | – | ||
| Healthcare | US | 2010 | 2011 | Trade Sale | – | ||
| Healthcare | France | 2010 | 2019 | Trade Sale | – | ||
| Healthcare | US | 2019 | 2022 | Trade Sale | – | ||
| Healthcare | US | 2013 | 2020 | IPO | – | ||
| Healthcare | US | 2017 | 2018 | IPO | – |
Mérieux Participations 1Buyoutdivesting2010 · 16yr€80M0 active · 1 realized
Realized
1 exit| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Healthcare | France | 2013 | 2019 | Trade Sale | – |
Saved GPs appear in your watchlist, one click from your workspace.
About Merieux Equity Partners
Mérieux Equity Partners is a leading European healthcare-specialised investment firm with €1.6 billion of assets under management as of December 2024, founded in 2009 and headquartered in Lyon. The firm operates through two dedicated platforms: Innovation (venture capital) and Buyout (growth and buyout), supporting the healthcare ecosystem across early-stage biotech innovation through to mid-cap healthcare buyout transactions, with the platform aligned with the broader Institut Mérieux life sciences industrial heritage.
Investment thesis
Mérieux Equity targets European and selectively North American healthcare companies across the development lifecycle, deploying dedicated venture commitments through the Innovation platform (early-stage biotech and HealthTech) plus growth and buyout equity through the Buyout platform (mid-cap healthcare services and products). Equity ticket sizes vary by strategy from venture-stage early commitments through to mid-cap healthcare growth equity positions. The exclusive healthcare sector focus enables deep clinical and regulatory expertise across portfolio companies.
Recent activity
Recent realised exits include Mabtech (healthcare, 2024), Mablink Bioscience (healthcare, 2023), Physioassist (healthcare, 2023), DOC Generici (healthcare, 2022) and Ivantis (healthcare, 2022), reflecting active distribution across the healthcare franchise. The platform tracks 6 funds, 34 active portfolio companies and 17 realised exits across the dual Innovation and Buyout programmes. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
France·€1.6B
France·€1.6B
France·€1.7B
France·€1.5B
France·€1.7B
France·€1.5B
France·€1.5B
France·€1.8B
France·€1.8B
France·€1.9B
France·€1.4B
France·€1.3BGet the full picture on Merieux Equity Partners.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in